DarioHealth (NASDAQ:DRIO) Stock Price Passes Below 200-Day Moving Average – Here’s What Happened

DarioHealth Corp. (NASDAQ:DRIO)’s stock price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $9.71 and traded as low as $7.00. DarioHealth shares last traded at $7.06, with a volume of 5,075 shares traded.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. Stifel Nicolaus reissued a “buy” rating and issued a $10.00 price objective on shares of DarioHealth in a research note on Thursday, May 14th. TD Cowen reaffirmed a “hold” rating and set a $11.00 target price on shares of DarioHealth in a research note on Wednesday, May 13th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $10.50.

DarioHealth Stock Performance

The firm has a market capitalization of $51.61 million, a price-to-earnings ratio of -0.80 and a beta of 1.11. The firm has a 50 day moving average price of $7.62 and a 200-day moving average price of $9.71. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.07 and a quick ratio of 2.62.

Hedge Funds Weigh In On DarioHealth

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Kestra Advisory Services LLC purchased a new stake in shares of DarioHealth during the fourth quarter worth approximately $35,000. Geode Capital Management LLC lifted its stake in DarioHealth by 167.9% in the fourth quarter. Geode Capital Management LLC now owns 49,567 shares of the company’s stock worth $564,000 after acquiring an additional 31,063 shares during the last quarter. Finally, XTX Topco Ltd lifted its stake in DarioHealth by 229.0% in the second quarter. XTX Topco Ltd now owns 62,511 shares of the company’s stock worth $42,000 after acquiring an additional 43,513 shares during the last quarter. Hedge funds and other institutional investors own 33.39% of the company’s stock.

About DarioHealth

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.